

LAMELLAR BIOMEDICAL LIMITED

**Company Registration Number:
SC312123 (Scotland)**

Unaudited abridged accounts for the year ended 30 June 2021

Period of accounts

Start date: 01 July 2020

End date: 30 June 2021

LAMELLAR BIOMEDICAL LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2021

Balance sheet

Notes

LAMELLAR BIOMEDICAL LIMITED

Balance sheet

As at 30 June 2021

	<i>Notes</i>	<i>2021</i>	<i>2020</i>
		£	£
Fixed assets			
Tangible assets:	3	114,871	324,649
Total fixed assets:		<u>114,871</u>	<u>324,649</u>
Current assets			
Debtors:		173,092	443,183
Cash at bank and in hand:		14,114	296,274
Total current assets:		<u>187,206</u>	<u>739,457</u>
Creditors: amounts falling due within one year:		(263,161)	(399,869)
Net current assets (liabilities):		<u>(75,955)</u>	<u>339,588</u>
Total assets less current liabilities:		<u>38,916</u>	<u>664,237</u>
Total net assets (liabilities):		<u>38,916</u>	<u>664,237</u>
Capital and reserves			
Called up share capital:		2,690	2,690
Share premium account:		14,949,936	14,949,936
Profit and loss account:		(14,913,710)	(14,288,389)
Shareholders funds:		<u>38,916</u>	<u>664,237</u>

The notes form part of these financial statements

LAMELLAR BIOMEDICAL LIMITED

Balance sheet statements

For the year ending 30 June 2021 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 20 September 2021
and signed on behalf of the board by:**

Name: Johnny Cordiner
Status: Director

The notes form part of these financial statements

LAMELLAR BIOMEDICAL LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2021

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LAMELLAR BIOMEDICAL LIMITED

Notes to the Financial Statements for the Period Ended 30 June 2021

2. Employees

	<i>2021</i>	<i>2020</i>
Average number of employees during the period	5	11

LAMELLAR BIOMEDICAL LIMITED

Notes to the Financial Statements for the Period Ended 30 June 2021

3. Tangible Assets

	Total
Cost	£
At 01 July 2020	741,909
Additions	712
Disposals	(220,208)
At 30 June 2021	<u>522,413</u>
Depreciation	
At 01 July 2020	417,260
Charge for year	98,752
On disposals	(108,470)
At 30 June 2021	<u>407,542</u>
Net book value	
At 30 June 2021	<u>114,871</u>
At 30 June 2020	<u>324,649</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.